Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 20/20 | 0.91 |
| ▸ | KCNK9 | Q9NPC2 | 20/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458027 | 1.00 | KCNK3 (0.91) | KCNK3KCNK9 | |
| SCHEMBL20587840 | 0.95 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432780 | 0.95 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL19807631 | 0.94 | KCNK3 (0.90) | KCNK3KCNK9 | |
| SCHEMBL29458007 | 0.92 | KCNK3 (0.78) | KCNK3KCNK9 | |
| SCHEMBL22916199 | 0.92 | KCNK3 (0.78) | KCNK3KCNK9 | |
| SCHEMBL22001495 | 0.91 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432774 | 0.91 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL20589071 | 0.90 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29458051 | 0.90 | KCNK3 (1.00) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118122-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | HYOU1, DDAH1, VDAC3 | KCNK3 145/4885KCNK9 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.